Successfully managing the demands of cell therapy supply chains – addressing the unique complexity of an autologous therapy supply chain
These therapies contain modified human cells that can regenerate or augment a recipient’s dysfunctional cells, tissues or organs. Cells’ biological characteristics are typically altered ex vivo before administration of the final product to patients.
Every constituent of the supply chain must be seamlessly orchestrated for a cell therapy product to reach every patient. From collection of cells through production into a drug product and reverse logistics back to the patient, this process is very complex but a risk based approach can mitigate potential challenges.
Download and read our insightful white paper which examines the process of successfully managing the unique demands of cell therapy supply chains and gain an understanding of:
- How product characteristics can influence your approach to managing the Cell Therapy supply chain.
- What might influence the decision to have centralized or localized manufacturing strategies
- The information that is required to successfully import and export Cell Therapy materials.
Download the full white paper by filling in the form below...